Prepare Yourself for Liftoff: Pacific Biosciences of California Inc (PACB)

With 8.58 million shares changed hands, the volume of the stock remained lighter than its average volume of 10.2 million shares. The 52-week range on PACB shows that it touched its highest point at $2.72 and its lowest point at $1.06 during that stretch. It currently has a 1-year price target of $2.00. Beta for the stock currently stands at 2.20.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PACB was down-trending over the past week, with a drop of -0.88%, but this was down by -22.76% over a month. Three-month performance dropped to -28.21% while six-month performance fell -56.08%. The stock lost -40.11% in the past year, while it has lost -38.80% so far this year. A look at the trailing 12-month EPS for PACB yields -2.77 with Next year EPS estimates of -0.57. For the next quarter, that number is -0.18. This implies an EPS growth rate of 21.98% for this year and 34.29% for next year. EPS is expected to grow by 26.73% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -23.55%.

Float and Shares Shorts:

At present, 300.04 million PACB shares are outstanding with a float of 264.11 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PACB since 11 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.17512 being high and -$1.94862 being low. For PACB, this leads to a yearly average estimate of -$1.35362. Based on analyst estimates, the high estimate for the next quarter is -$0.13 and the low estimate is -$0.17. The average estimate for the next quarter is thus -$0.16.